Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron’s REVeRT technology
25 oct. 2023 08h00 HE
|
ViGeneron GmbH
REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packaging size in various tissuesPotential to address prevalent inherited diseases...
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
24 oct. 2023 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Hefei Municipal Government and EHang Announce Strategic Partnership in Low-Altitude Economy with US$100 Million Support Plan
18 oct. 2023 09h29 HE
|
EHang Holdings Limited
GUANGZHOU, China, Oct. 18, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading urban air mobility (“UAM”) technology platform company,...
EHang Successfully Obtains Type Certificate for EH216-S Passenger-Carrying UAV System Issued by Civil Aviation Administration of China
13 oct. 2023 04h57 HE
|
EHang Holdings Limited
GUANGZHOU, China, Oct. 13, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading urban air mobility (“UAM”) technology platform company,...
Coave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery Platform
12 oct. 2023 07h00 HE
|
Coave Therapeutics
Paris, France, October 12th, 2023– Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces the formation of its new Scientific Advisory Board...
Nasdaq Approves EHang’s Request to Suspend Trading of ADSs until no later than October 13, 2023 Pending Material Announcement
09 oct. 2023 09h15 HE
|
EHang Holdings Limited
GUANGZHOU, China, Oct. 09, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
[Latest] Global Hemophilia B Gene Therapy Market Size/Share Worth USD 5,938.5 Billion by 2032 at a 34.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
27 sept. 2023 16h00 HE
|
Custom Market Insights
Austin, TX, USA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hemophilia B Gene Therapy Market Size, Trends and Insights By Treatment Type...
EHang Strategically Invests in Solid-State Lithium Metal Battery Tech Company Inx to Develop Solid-State Battery Supply Chain for eVTOLs
20 sept. 2023 07h26 HE
|
EHang Holdings Limited
GUANGZHOU, China, Sept. 20, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform...
Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval
13 sept. 2023 03h00 HE
|
Rentschler Biopharma SE
UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapyHighly experienced team ready to support ATMP innovators at all stagesOffering comprehensive range of...
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
07 sept. 2023 17h00 HE
|
Shape Therapeutics, Inc.; Otsuka
TOKYO and SEATTLE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce...